Discounted Cash Flow (DCF) Analysis Levered
Sangamo Therapeutics, Inc. (SGMO)
$0.6933
-0.08 (-10.14%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 84.45 | 102.43 | 118.19 | 110.70 | 111.30 | 119.89 | 129.15 | 139.12 | 149.85 | 161.42 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | 37.15 | -144.40 | 169.88 | -233.25 | -223.63 | -87.49 | -94.25 | -101.52 | -109.36 | -117.80 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -43.07 | -20.67 | -14.71 | -23.28 | -20.17 | -29.44 | -31.71 | -34.16 | -36.80 | -39.64 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -5.91 | -165.08 | 155.16 | -256.53 | -243.80 | -116.93 | -125.96 | -135.68 | -146.16 | -157.44 |
Weighted Average Cost Of Capital
| Share price | $ 0.6,933 |
|---|---|
| Beta | 1.105 |
| Diluted Shares Outstanding | 154.34 |
| Cost of Debt | |
| Tax Rate | -0.22 |
| After-tax Cost of Debt | -21.88% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 9.757 |
| Total Debt | 43.11 |
| Total Equity | 107.01 |
| Total Capital | 150.12 |
| Debt Weighting | 28.72 |
| Equity Weighting | 71.28 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 84.45 | 102.43 | 118.19 | 110.70 | 111.30 | 119.89 | 129.15 | 139.12 | 149.85 | 161.42 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 37.15 | -144.40 | 169.88 | -233.25 | -223.63 | -87.49 | -94.25 | -101.52 | -109.36 | -117.80 |
| Capital Expenditure | -43.07 | -20.67 | -14.71 | -23.28 | -20.17 | -29.44 | -31.71 | -34.16 | -36.80 | -39.64 |
| Free Cash Flow | -5.91 | -165.08 | 155.16 | -256.53 | -243.80 | -116.93 | -125.96 | -135.68 | -146.16 | -157.44 |
| WACC | ||||||||||
| PV LFCF | -116.16 | -124.29 | -132.99 | -142.31 | -152.27 | |||||
| SUM PV LFCF | -668.01 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 0.67 |
| Free cash flow (t + 1) | -160.59 |
| Terminal Value | 12,074.35 |
| Present Value of Terminal Value | 11,677.87 |
Intrinsic Value
| Enterprise Value | 11,009.85 |
|---|---|
| Net Debt | -57.34 |
| Equity Value | 11,067.19 |
| Shares Outstanding | 154.34 |
| Equity Value Per Share | 71.70 |